Navigation Links
Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
Date:7/23/2009

TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the Boca Raton Resort & Club in Florida.

More information about the conference can be found at www.jesuplamontconferences.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                     Media
    info@peregrineinc.com                         Barbara Lindheim
    (800) 987-8256                                (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Blueprint Medicines (NASDAQ: BPMC ) today ... of 9,367,708 shares of common stock at a ... shares of common stock issued upon the full ... purchase additional shares. The gross proceeds from the ... $168.6 million, before underwriting discounts and estimated offering expenses. ...
(Date:5/5/2015)... 2015 Hayden-McNeil is pleased ... custom course materials for smaller courses. This program is ... as 200 students. , “I’m very excited about ... higher education instructors,” said Jeff McCarthy, Hayden-McNeil president. “By ... do our part to make education both more effective ...
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, a ... heart failure and other chronic diseases, has engaged ... analysis designed to reflect the healthcare patterns of ... model will be used to characterize the impact ... have on those groups of patients and the ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Franz Inc ... technology, today announced that its flagship product, AllegroGraph, has been ... Graph Database Market Update report. AllegroGraph is a ... the W3C industry standards. Graph databases are skyrocketing in popularity ... according to a recent DBMS ranking by DB-Engines. ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... populations with regard to risk associated in the development of ... osteoporosis or cardiovascular disease, - North American ... in response to nutritional products (nutrigenomics),- North ... Feb. 28 Interleukin Genetics,Inc. (Amex: ILI ) reported today ...
... the following Webcast:, What: Transgenomic Inc. Fourth ... Conference Call, When: Thursday, February 28, ... How: Live over the Internet -- Simply ... address above., To access the call via telephone, ...
... SAN DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ... in a,Phase I study of ANA773, the company,s oral ... first-in-human trial is a safety,and tolerability study designed to ... as to select the dose and,schedule for Phase II ...
Cached Biology Technology:Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 2Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 3Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 4Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4
(Date:4/20/2015)... -- Huntington Memorial Hospital is the first facility in ... wireless monitoring sensor to manage heart failure (HF). The ... heart failure monitoring device that has been proven to ... manage heart failure. The CardioMEMS HF System ... artery (PA) during a non-surgical procedure to directly measure ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... Biology, researchers report using DNA from tissues samples collected in 1955 ... ( Orcinus orca ). In 1955, a pod ... a skeleton was saved in a museum in Wellington. Photographs were ... form of killer whale, characterized by a very small white eye-patch ...
... A decade-long JDRF-funded study led by the Institute ... providing a deeper understanding of the link between autoantibodies ... highlighting the importance of pre-diabetes research into possible preventions ... Autoantibodies and Risk of Progression to Diabetes in Children," ...
... 19, 2013  New York College of Health Professions announces the ... Office for detecting biometric changes through smart phones, apps and ... or killed. This patent is part of an ... College of Health Professions. Lisa Pamintuan , ...
Cached Biology News:New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... He biolistic system enables 7-10 times more cells ... fits into the shocking chamber of the PDS-1000 ... wave over 7 microcarriers. By uniformly spreading the ... area, the system maximizes the number of cells ...
... BioLogic LP system, 220-240 V, is ... fraction collection. The system includes the ... kit with MV-6 injection valve, proportioning ... cell, tubing and fittings kit, column ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system with colony-picking capabilities, ... to array DNA, proteins, oligonucleotides, carbohydrates, lipids, ... substrates for microarray applications. This system can ... small as 300 micrometers in diameter and ...
Biology Products: